<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><identifier>ir-100-17286</identifier><datestamp>2014-12-29T06:15:34Z</datestamp><dc:title>Total synthesis of MECA-79</dc:title><dc:creator>BEHERA, A</dc:creator><dc:creator>EMMADI, M</dc:creator><dc:creator>KULKARNI, SS</dc:creator><dc:subject>GLYCOPEPTIDE ANTIGENS</dc:subject><dc:subject>ANTICANCER VACCINES</dc:subject><dc:subject>BUILDING-BLOCKS</dc:subject><dc:subject>D-GLUCOSAMINE</dc:subject><dc:subject>L-SELECTIN</dc:subject><dc:subject>CARBOHYDRATE</dc:subject><dc:subject>THIOGLYCOSIDES</dc:subject><dc:subject>GLYCOSYLATION</dc:subject><dc:subject>LIGAND</dc:subject><dc:description>The MECA-79 antigen is a sulfated mucin type core-1 extended O-glycan which is a potential anti-inflammatory agent. Herein we report a total synthesis of MECA-79 via a convergent [2 + 2] glycosylation route. The synthesis relies on efficient transformation of D-glucosamine into the orthogonally protected Tn antigen derivative and its elaboration into the TF antigen en route to MECA-79.</dc:description><dc:publisher>ROYAL SOC CHEMISTRY</dc:publisher><dc:date>2014-12-29T06:15:34Z</dc:date><dc:date>2014-12-29T06:15:34Z</dc:date><dc:date>2014</dc:date><dc:type>Article</dc:type><dc:identifier>RSC ADVANCES, 4(102)58573-58580</dc:identifier><dc:identifier>2046-2069</dc:identifier><dc:identifier>http://dx.doi.org/10.1039/c4ra12631a</dc:identifier><dc:identifier>http://dspace.library.iitb.ac.in/jspui/handle/100/17286</dc:identifier><dc:language>English</dc:language></oai_dc:dc>